Supplemental files



Figure S1. The transfection efficiency of lentivirus in RPMI8226 cells

(A) The ALKBH5 mRNA level in oe-ALKBH5 and sh-ALKBH5 RPMI8226 cells. (B) The expression levels of ALKBH5 in oe-ALKBH5 and sh-ALKBH5 myeloma cells. (C) Representative images of transfected RPMI8226 cells under fluorescence microscopy. White: general microscopy field, Green: fluorescence microscopy field, bar=100µm***P<0.001.





Group3



Figure S2. The expression of ALKBH5 from individual patient examined by western blot

Patient	Gender	Age	MM	LDH	β2-MG	Serum	MM-FISH
		(year)	stage	(U/L)	(mg/L)	Albumin	
			(ISS)			(g/L)	
1	female	50	II	75	4.7	23.3	t(4;14)(p16;q32)
2	male	68	III	90	7.5	24.5	
3	female	71	Ι	139	1.9	39.6	
4	male	65	Ι	187	1.4	38.5	
5	female	69	Ι	89	3.2	36	t(4;14)(p16;q32)
6	female	57	III	305	17.1	38.6	t(4;14)(p16;q32)
7	male	57	Ι	149	1.2	43	
8	female	74	II	300	3.9	19	
9	female	73	III	325	13.1	27.7	t(4;14)(p16;q32)
10	female	63	III	225	59.3	21.4	
11	female	57	II	320	4.3	20	
12	female	71	Ι	197	2.2	36.7	
13	female	69	III	288	3.6	30.9	
14	female	69	Ι	99	3.1	37.8	
15	female	56	II	165	5.1	35	
16	male	59	III	340	7.5	18.6	
17	female	59	Ι	125	1.6	32.7	
18	female	71	Ι	150	2.5	41.2	
19	female	74	II	136	4.7	32.5	
20	male	81	III	129	8.5	35.1	
21	female	68	Ι	205	1.8	36.1	
22	female	69	III	166	7.6	32	t(11;14)(q13;q32)
23	female	64	Ι	254	2.8	39.5	
24	male	65	III	183	13	28.8	
25	male	66	III	220	5.6	17.9	

Table S1. The patients' information



Figure S3. Stastical diaram of the IHC result of figure 3C

(A)-(F) Qualification of ALKBH5, YAP, SAV1, caspase 3, BCL-2, BAX, Ki67 and pAKT IHC result

in the ALKBH5⁻ and control cell populations. ***P<0.001,****P<0.0001.



Figue S4. The in vivo cell derived xenograft models showed that tumors from oe-

ALKBH5+sh-NC group had an increase in tumor volume and significantly

delayed in ALKBH5-overexpression and SAV1-silencing group.